Li Y-R*, Wilson M*, and Yang L. (*Co-first authors) Target tumor microenvironment by innate T cells. Front Immunol. 2022, 13:999549. [Frontiers in Immunology  PDF]

Brown J, Li Z, Wang X, Kim YJ, Wang Y-C, Zuo Y, Hong W, Wang P, Li B*, and Yang L*. (*Co-corresponding authors) Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects. Front Pharmacol. 2022, 13:970324. [Frontiers in Pharmacology  PDF]

Li Y-R*, Zeng S*, Dunn ZS, Zhou Y, Li Z, Yu J, Wang Y-C, Ku J, Cook N, Kramer A, and Yang L. (*Co-first authors) Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. iScience. 2022, 25(9):104859. August 16, epub ahead of print. [iScience  PDF][UCLA News  PDF]

Li Y-R, Zhou Y, Wilson M, Kramer A, Hon R, Zhu Y, Fang Y, and Yang L. Tumor-localized administration of α-GalCer to recruit invariant natural killer T cells and enhance their antitumor activity against solid tumors. Int J Mol Sci. 2022, 23(14):7547. [International Journal of Molecular Sciences  PDF]

Zhou Y*, Husman Tiffany*, Cen X, Tsao T, Brown J, Bajpai A, Li M, Zhou K, and Yang L. (*Co-first authors). Interleukin 15 in cell-based cancer immunotherapy. Int J Mol Sci. 2022, 23(13):7311. [International Journal of Molecular Sciences  PDF]

Lee D, Rosenthal CJ, Penn NE, Dunn ZS, Zhou Y, and Yang L. Human γδ T cell subsets and their clinical applications for cancer immunotherapy. Cancers. 2022, 14(12):3035. [Cancers  PDF]

Li Y-R, Brown J, Yu Y, Lee D, Zhou K, Dunn ZS, Hon R, Wilson M, Kramer A, Zhu Y, Fang Y, and Yang L. Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity. Cancers. 2022, 14(11):2749. [Cancers  PDF]

Li Y-R*, Yu Y*, Kramer A, Hon R, Wilson M, Brown J, and Yang L. (*Co-first authors). An ex vivo 3D tumor microenvironment-mimicry culture to study TAM modulation of cancer immunotherapy. Cells. 2022, 11(9):1583. [Cells  PDF]

Zhou Y*, Li M*, Zhou K*, Brown J, Tsao T, Cen X, Husman T, Baipai A, Dunn ZS, and Yang L. (*Co-first authors). Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy. Cancers. 2022, 14(9):2266. [Cancers  PDF]

Yang L. Q&A. Cell Rep Med. 2022, 3:100616. [Cell Reports Medicine  PDF]

Dunn ZS, Li Y-R, Yu Y, Lee D, Gibbons A, Kim JJ, Zhou TY, Li M, Nguyen M, Cen X, Zhou Y, Wang P, and Yang L. Minimally invasive preclinical monitoring of the peritoneal cavity tumor microenvironment. Cancers. 2022, 14(7):1775. [Cancers  PDF]

Li Y-R, Dunn ZS, Garcia Jr. G, Carmona C, Zhou Y, Lee D, Yu J, Huang J, Kim JT, Arumugaswami V, Wang P, and Yang L. Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. Stem Cell Res Ther. 2022, 13(1):112. [Stem Cell Research & Therapy  PDF] [UCLA Blog  PDF]

Brown J§, Li B§*, and Yang L*. (§Co-first authors; *Co-Corresponding authors). MAOI  antidepressants: could they be a next-generation ICB therapy? Front Immunol. 2022, 13:853624. [Frontiers in Immunology  PDF]

Nesterenko PA, McLaughlin J, Tsai BL, Sojo GB, Cheng D, Zhao D, Mao Z, Bangayan NJ, Obusan MB, Su Y, Ng RH, Chour W, Xie J, Li Y-R, Lee D, Noguchi M, Carmona C, Phillips JW, Kim JT, Yang L, Heath JR, Boutros PC, and Witte ON. HLA-A*02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. Cell Rep. 2021, 37(13):110167. [Cell Reports  PDF]

Li Y-R*, Dunn ZS*, Zhou Y, Lee D, and Yang L. (*Co-first authors). Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies. Cells. 2021, 10(12):3497. [Cells  PDF]

Li Y-R, Zhou Y, Kramer A, and Yang L. Engineering stem cells for cancer immunotherapy. Trends Cancer. 2021, 7(12):1059-1073. [Trends in Cancer  PDF]

Li Y-R*, Zhou Y*, Kim Y, Zhu Y, Ma F, Yu J, Wang Y-C, Chen X, Li Z, Zeng S, Wang X, Lee D, Ku J, Tsao T, Hardoy C, Huang J, Cheng D, Montel-Hagen A, Seet CS, Crooks GM, Larson SM, Sasine JP, Wang X, Pellegrini M, Ribas A, Kohn DB, Witte O, Wang P, and Yang L. (*Co-first authors). Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med. 2021, 2(11):100449. [Cell Reports Medicine  PDF][UCLA News  PDF][BSCRC News  PDF][JCCC News  PDF][Life Sciences News  PDF][Science Daily  PDF][CIRM Blog  PDF]

Zhou Y, Li Y, Zeng S, and Yang L. Methods for studying mouse and human invariant natural killer T cells. Methods Mol Biol. 2021; 2388: 35-57. [Methods in Molecular Biology  PDF]

Wang Y-C, Wang X, Yu J, Ma F, Li Z, Zhou Y, Zeng S, Ma X, Li Y-R, Neal A, Huang J, To A, Clarke N, Memarzadeh S, Pellegrini M, and Yang L. Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy. Nat Commun. 2021, 12:3530. [Nature Communications  PDF][UCLA News  PDF][CBS News  PDF][NBC News  PDF][Fierce Biotech News  PDF][Drug Target Review News  PDF]

Wang X, Li B, Kim Y, Wang Y, Li Z, Yu J, Zeng S, Ma X, Choi I, Di Biase S, Smith DJ, Zhou Y, Li Y, Ma F, Huang J, Clarke N, To A, Gong L, Pham A, Moon H, Pellegrini M, and Yang L. Targeting monoamine oxidase A for T cell-based cancer immunotherapy. Sci Immunol. 2021, 6:eabh2383. [Science Immunology  PDF][Science Magazine News  PDF][UCLA News  PDF][CBS News  PDF][NBC News  PDF][Fierce Biotech News  PDF][Drug Target Review News  PDF]

Li B* and Yang L*. (Co-corresponding authors). Creatine in T cell antitumor immunity and cancer immunotherapy. Nutrients. 2021, 13(5):1633. [Nutrients  PDF]

Li Z, Lee D, Zeng S, and Yang L. Successes and challenges of NKT cell immunotherapy: breaking tolerance to cancer resistance. In: Successes and Challenges of NK Immunotherapy. Academic Press: Elsevier. Book 2021, Pages 63-80. [Book Link][Chapter 4 Link  PDF]

 

Di Biase S*, Ma X*, Wang X, Yu J, Wang Y-C, Smith DJ, Zhou Y, Li Z, Kim YJ, Clarke N, To A, and Yang L. (*Co-first authors). Creatine uptake regulates CD8 T cell antitumor immunity. J Exp Med. 2019, 216(12): 2869-2882. [JEM  PDF][UCLA News  PDF][UC News  PDF][MedicalXpress  PDF][ScienceDaily  PDF][The Medical News  PDF][Technology Networks  PDF]

Zhu Y*, Smith DJ*, Zhou Y, Li YR, Yu J, Lee D, Wang Y-C, Di Biase S, Wang Xi, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu GR, Ribas A, Kohn DB, Witte ON, and Yang L. (*Co-first authors). Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer. Cell Stem Cell. 2019, 25(4):542-557. Epub 2019  Sept 5. [Cell Stem Cell  PDF][CSC Highlight  PDF][UCLA BSCRC News  PDF][UCLA Health News  PDF][Medical News Today  PDF][SciTechDaily  PDF][The Stem Cell Podcast  PDF]

Puig-Saus C, Parisi G, Garcia-Diaz A, Krystofinski PE, Sandoval S, Zhang R, Champhekar AS, McCabe J, Cheung-Lau GC, Truong NA, Vega-Crespo A, Komenan MDS, Pang J, Macabali MH, Saco JD, Goodwin JL, Bolon B, Seet CS, Montel-Hagen A, Crooks GM, Hollis RP, Campo-Fernandez B, Bischof D, Cornetta K, Gschweng EH, Adelson C, Nguyen A, Yang L, Witte ON, Baltimore D, Comin-Anduix B, Kohn DB, Wang X, Cabrera P, Kaplan-Lefko PJ, Berent-Maoz B, and Ribas A. IND-enabling studies for a clinical trial to genetically program a persistent cancer-targeted immune system. Clin Cancer Res. 2019, 25(3):1000-1011. [Clinical Cancer Research  PDF]

Bethune MT§, Li XH§, Yu J§, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Saus CP, Cebon J, Ribas A, Yang L*, Witte ON*, and Baltimore D*. (§Co-first authors; *Co-corresponding authors). Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proc Natl Acad Sci U S A. 2018, 115(45): E107002-E10711. [PNAS  PDF]

Siegler EL, Zhu Y, Wang P*, and Yang L*. (*Co-corresponding authors). Off-the-shelf  CAR-NK cells for cancer immunotherapy. Cell Stem Cell. 2018, 23(8):160-161. [Cell Stem Cell  PDF]

Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, and Comin-Anduix B. Characterization of postinfusion phenotypic differences in fresh versus cryopreserved TCR engineered adoptive cell therapy products. J Immunother. 2018, 41(5):248-259. [Journal of Immunotherapy  PDF]

Li B*, Wang X*, Choi I, Liu S, Pham A, Moon H, Rao DS, Boldin MP, and Yang L. (*Co-first authors). miR-146a modulates autoreactive CD4 T cell Th17 differentiation and regulates T cell-mediated autoimmunity. J Clin Invest. 2017, 127(10):3702-3716. [Journal of Clinical Investigation  PDF]

Kim JT, Liu Y, Kulkarni RP, Lee KK, Dai BB, Lovely G, Ouyang Y, Wang P, Yang L, and Baltimore D. Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation. Sci Immunol. 2017, 2:eaal1329. [Science Immunology  PDF]

Smith DJ, Lin LJ, Moon H, Pham AT, Wang X, Liu S, Ji S, Rezek V, Shimizu S, Ruiz M, Lam J, Janzen DM, Memarzadeh S, Kohn DB, Zack JA, Kitchen SG, An DS, and Yang L. Propagating humanized BLT mice for the study of human immunology and immunotherapy. Stem Cells Dev. 2016, 25(24):1863-1873. [Stem Cells and Development  PDF]

Smith DJ, Liu S, Ji S, Li B, McLaughlin J, Cheng D, Witte ON, and Yang L. Genetic Engineering of hematopoietic stem cells to generate invariant natural killer T cells. Proc Natl Acad Sci U S A. 2015, 112(5):1523-1528. [PNAS  PDF][Hematopoiesis News  TOP STORY]

Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJL, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, and Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014, 20(9): 2457-2465. [Clinical Cancer Research  PDF]

Yang L* and Wang P. (*Co-corresponding author). Passive immunization against HIV/AIDS by antibody gene transfer. Viruses. 2014, 6(2): 428-447. [Viruses  PDF]

Hur EM, Patel SN, Shimizu S, Rao D, Gnanapragasam PNP, An DS, Yang L*, and Baltimore D*. (*Co-corresponding authors). Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood. 2012, 120(23): 4571-4582. [Blood  PDF]

Yu KK, Aguilar K, Tsai J, Galimidi R, Gnanapragasam P, Yang Land Baltimore D. Use of  mutated self-cleaving 2A peptides as a molecular rheostat to direct simultaneous formation of membrane and secreted anti-HIV immunoglobulins. PLoS One. 2012, 7(11):e50438. [PLoS One  PDF]

Yang L*, Boldin MP, Yu Y, Liu CS, Ea CK, Taganov KD, Zhao JL, and Baltimore D*. (*Co-corresponding authors). miR-146a controls the resolution of T cell responses in mice. J Exp Med. 2012, 209(9): 1655-1670. [Journal of Experimental Medicine  PDF]

Xiao L, Kim J, Lim M, Dai B, Yang L, Reed S, Baltimore D, and Wang P. A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses. Vaccine. 2012, 30(15): 2570-2581. [Vaccine  PDF]

Balazs AB, Chen J, Hong CM, Rao DS, Yang L, and Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011, 481(7379): 81-84. [Nature  PDF]

Yang L*, Yu Y, Kalwani M, Tseng TW, and Baltimore D*. (*Co-corresponding authors). Homeostatic cytokines orchestrate the segregation of CD4 and CD8 memory T-cell reservoirs in mice. Blood. 2011, 118(11): 3039-3050. [Blood  PDF]

Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J, Sun G, Tay J, Linsley PS, and Baltimore D. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011, 208(6): 1189-1201. [Journal of Experimental Medicine  PDF]

Luo XM, Lei MY, Feidi RA, West AP Jr, Balazs AB, Bjorkman PJ, Yang L*, and Baltimore D*. (*Co-corresponding authors). Dimeric 2G12 as a potent protection against HIV-1. PLoS Pathog. 2010, 6(12): e1001225. [PLoS Pathogens  PDF]

O’Connell RM, Balazs AB, Rao DS, Kivork C, Yang L*, and Baltimore D*. (*Co-corresponding authors). Lentiviral vector delivery of human interleukin-7 (hIL-7) to human immune system (HIS) mice expands T lymphocyte populations. PLoS One. 2010, 5(8): e12009. [PLoS One  PDF]

Baltimore D, Witte ON, Yang L, Economou J, and Ribas A. Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma. Pigment Cell Melanoma Res. 2010, 23(2): 288-289. [Pigment Cell & Melanoma Research  PDF]

Dai B, Yang L, Yang H, Hu B, Baltimore D, and Wang P. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci U S A. 2009, 106(48): 20382-20387. [PNAS  PDF]

Luo XM, Maarschalk E, O’Connell RM, Wang P, Yang L*, and Baltimore D*. (*Co-corresponding authors). Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood. 2009, 113(7): 1422-1431. [Blood  PDF]

Ziegler L, Yang L, Joo Ki, Yang H, Baltimore D, and Wang P. Targeting lentiviral vectors to antigen-specific immunoglobulins. Hum Gene Ther. 2008, 19(9): 861-872. [Human Gene Therapy  PDF]

Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty NG, Ray S,   Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A,   Economou JS, Baltimore D, and Mukherji B. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol. 2008, 181(2): 1063-1070. [Journal of Immunology  PDF]

Yang L*, Yang H*, Rideout K, Cho T, Joo KI, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D§, and Wang P§. (*Co-first authors; §Co-corresponding authors). Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol. 2008, 26(3): 326-334. [Nature Biotechnology  PDF]

Yang L, Bailey L, Baltimore D*, and Wang P*. (*Co-corresponding authors). Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A. 2006, 103(31): 11479-11484. [PNAS  PDF]

Yang L and Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci U S A. 2005, 102(12): 4518-4523. [PNAS  PDF]

Bridges R, Rigero B, Byrnes E, Yang L, and Walker A. Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats. Endocrinology. 2001, 142(2): 730-739. [Endocrinology  PDF]

Yang L, Kuo CB, Liu Y, Coss D, Xu X, Chen C, Oster-Granite ML, and Walker AM. Administration of unmodified prolactin (U-PRL) and a molecular mimic of phosphorylated prolactin (PP-PRL) during rat pregnancy provides evidence that the U-PRL:PP-PRL ratio is crucial to the normal development of pup tissues. J Endocrinol. 2001, 168(2): 227-238. [Journal of Endocrinology  PDF]

Coss D, Yang L, Kuo CB, Xu X, Luben RA, and Walker AM. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab. 2000, 279(6): E1216-E1225. [Endocrinology and Metabolism  PDF]

Coss D, Kuo CB, Yang L, Ingleton P, Luben R, and Walker AM. Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin. Endocrinology. 1999, 140(11): 5087-5094. [Endocrinology  PDF]